MTK Antibody
Description
Definition and Classification of MTK Antibodies
MTK antibodies are monoclonal antibodies (mAbs) produced using hybridoma technology, where immortalized hybrid cells generate uniform antibodies targeting specific epitopes. The "MTK" designation typically refers to clone identifiers, such as MTK1, MTK2, or MTK2113, each with distinct antigen-binding properties .
| Antibody Clone | Target Antigen | Host Species | Application |
|---|---|---|---|
| MTK1 | Human c-kit receptor | Mouse | Hematopoietic stem cell research |
| MTK2 | Human c-kit receptor | Mouse | Biomarker analysis |
| MTK2113 | Keyhole limpet hemocyanin | Mouse | ELISA diagnostics |
Development and Production
MTK antibodies are generated through:
-
Hybridoma Technology: Fusion of B cells from immunized mice with myeloma cells to create immortalized cell lines .
-
Biotin Conjugation: MTK2113 is conjugated with biotin for enhanced detection in immunoassays, purified via affinity chromatography .
-
Specificity Validation: MTK1 and MTK2 were validated using Western blot and cell proliferation assays, confirming their specificity for the c-kit receptor .
MTK1 and MTK2 in Hematopoiesis
-
Function: MTK1 inhibits stem cell factor (SCF)-induced proliferation in megakaryoblastic leukemia cells (M-MOK) and suppresses granulocyte-macrophage colony formation .
-
Therapeutic Potential: Demonstrated efficacy in concentrating bone marrow stem cells (CFU-GM, BFU-E), aiding in leukemia research .
MTK2113 in Diagnostics
-
Reactivity: Targets keyhole limpet hemocyanin (KLH), a carrier protein used in vaccine development .
-
Performance: Optimal ELISA detection at 0.5–2.0 µg/ml, with linear sensitivity between 5–300 ng/ml KLH .
Clinical and Therapeutic Implications
| Application | Mechanism | Reference |
|---|---|---|
| Cancer Research | Targets c-kit receptor on leukemia cells | |
| Infectious Disease | Binds KLH for pathogen detection | |
| Autoimmune Studies | Modulates cytokine signaling pathways |
Challenges and Future Directions
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
MTK Antibody catalyzes the phosphorylation of methylthioribose into methylthioribose-1-phosphate within the methionine cycle. This enzyme plays a crucial role in maintaining AdoMet homeostasis and is essential for sustaining high rates of ethylene synthesis.
- Vascular transcriptome analyses in Arabidopsis thaliana revealed phloem-specific expression of the Yang cycle gene 5-METHYLTHIORIBOSE KINASE1 (MTK1). PMID: 21540433
- Insertional mutagenesis of the unique AtMTK gene in Arabidopsis (Arabidopsis thaliana) resulted in an inability of plants to utilize methylthioadenosine as a supplemental sulfur source. PMID: 15557090
Q&A
Here’s a structured FAQ collection for researchers investigating MTK Antibody, synthesized from peer-reviewed studies and technical methodologies:
Advanced Research Questions
How can MTK Antibody overcome the "binding site barrier" in solid tumors?
-
Solution: Engineer lower-affinity variants to improve tumor penetration while maintaining target engagement .
-
Validation: Compare tumor-to-serum ratios of high- vs. low-affinity variants using quantitative PET imaging .
What computational tools resolve contradictions in MTK Antibody epitope mapping data?
-
Workflow:
How do researchers address MTK Antibody immunogenicity in preclinical models?
-
Strategy:
Table 1: Antibody Engineering Strategies for Enhanced Intracellular Delivery
| Strategy | Mechanism | Efficacy (IC₅₀) | Limitations |
|---|---|---|---|
| Cell-penetrating motifs | Covalent fusion with TAT peptide | 12 nM | Off-target uptake in normal cells |
| pH-sensitive linkers | Release payload in acidic endosomes | 8 nM | Premature cleavage in serum |
| Bispecific formats | Engage tumor antigen + T-cell | 5 nM | Risk of cytokine release syndrome |
Table 2: PK/PD Optimization Techniques
| Parameter | Optimization Method | Outcome |
|---|---|---|
| Half-life | Fc engineering (YTE mutation) | ↑ from 7d to 21d in NHPs |
| Tumor penetration | Affinity tuning (KD: 10⁻⁸ → 10⁻⁷ M) | ↑ Tumor-to-plasma ratio by 3.2x |
| Clearance | Site-specific PEGylation | ↓ Hepatic uptake by 40% |
Data Contradiction Analysis
Case Study: Conflicting reports on MTK Antibody efficacy in BRCA1-mutant vs. wild-type cancers.
